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Despite the fact that acne may be the
most common skin disease, it is clear
that there are missing pieces in its puz-
zling pathogenesis. This excellent work
by Kistowska et al. (2014) validates the
recent work of Qin et al. (2014) and
takes the field one step closer to
understanding the immunologic
mechanisms at play in acne. Important
next steps would be to examine the
mechanisms by which P. acnes
activates the innate immune response
within the unique microenvironments
that arise during acne lesion develop-
ment and to examine the respective
roles of IL-1a and IL-1b in this process.
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The Adverse Effect of IFN Gamma on
Stratum Corneum Structure and
Function in Psoriasis and Atopic
Dermatitis
Kenneth R. Feingold1
There is a marked increase in cytokines, including interferon gamma, in cutaneous
diseases such as atopic dermatitis and psoriasis. In this issue of the Journal,
Tawada and colleagues demonstrate that the quantity of ultra long–chain
ceramides in the stratum corneum, which play a key role in maintaining the
permeability barrier, is reduced in atopic dermatitis and psoriasis. Further, they
demonstrate that interferon gamma decreases the expression of the enzymes
required for the synthesis of these ultra long–chain ceramides (ELOVLs and
ceramide synthase 3). These results suggest that an increase in interferon gamma
by decreasing the key enzymes required for the synthesis of ultra long–chain
ceramides could further impair permeability barrier function, thereby exacerbat-
ing the pathological changes.
Journal of Investigative Dermatology (2014) 134, 597–600. doi:10.1038/jid.2013.440
It has long been recognized that cyto-
kines, such as tumor necrosis factor
(TNF), IL-1, IL-6, and the IFNs, regulate
lipid metabolism (Hardardottir et al.,
1994; Khovidhunkit et al., 2004).
Studies in the 1980s demonstrated that
TNF and other cytokines would inhibit
fat accumulation in adipocytes by
decreasing the activity of lipoprotein
lipase and by inhibiting fatty acid
synthesis. In contrast, in the liver, TNF
and other cytokines stimulate lipid
synthesis and VLDL production, which
contributes to the elevation in serum
triglyceride levels that characteristically
occurs during infections and inflam-
matory diseases. Over the ensuing
years, cytokines have been shown to
affect a large number of different lipid
metabolic pathways in a wide variety
of tissues (Hardardottir et al., 1994;
Khovidhunkit et al., 2004). Not surpri-
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singly, cytokines can also regulate
various aspects of lipid metabolism in
the epidermis.
Following permeability barrier disrup-
tion, there is a marked increase in the
expression of TNF, IL-1, IL-6, IL-8, IL-10,
and IFN gamma in the epidermis,
with no change in IL-2, IL-3, IL-4, or
IL-5 expression (Wood et al., 1992;
Nickoloff and Naidu, 1994; Wood
et al., 1997). Furthermore, increases in
these cytokines accelerate permeability
barrier repair by stimulating the
synthesis of lipids that are required for
the formation of lamellar bodies and
restoration of lamellar membranes in
the stratum corneum (Feingold and
Denda, 2012). Thus, increased cyto-
kine production following permeability
barrier perturbation can have beneficial
effects, and the failure to increase
cytokine production can have adverse
effects. For example, restoration of
permeability barrier function is delayed
in aged mice owing to a decrease in the
expression of IL-1 alpha, leading to
reduced lipid synthesis in keratinocytes
(Ye et al., 2002; Barland et al., 2004).
Treatment with IL-1 accelerates perme-
ability barrier recovery following its
disruption (Barland et al., 2004).
There is a marked increase in the
expression of a wide variety of cytokines
in cutaneous diseases such as psoriasis
and atopic dermatitis. Although follow-
ing acute permeability barrier disruption
the increase in cytokines is beneficial in
these chronic disorders, it is likely that
the increase in cytokine production
could affect lipid metabolism adversely
and thereby contribute to skin patho-
logy. For example, Hatano et al. (2005)
and Sawada et al. (2012) have both
shown that IL-4 inhibits the expres-
sion of acid sphingomyelinase and
beta-glucocerebrosidase, resulting in a
decrease in ceramide levels in the
stratum corneum (Hatano et al., 2005,
2007; Sawada et al., 2012). This results
in increased transepidermal water loss,
a marker of impaired permeability
barrier function.
In this issue of the Journal, Tawada
et al. (2014) provide evidence that
IFN gamma has an important role in
inducing alterations in ceramide
composition in the stratum corneum of
patients with atopic dermatitis and
psoriasis. Using matrix-assisted laser
desorption/ionization time-of-flight
mass spectrometry, the authors demon-
strate that the quantity of high total
carbon number ceramides is reduced
in both psoriasis and atopic dermatitis,
compared with normal controls (i.e.,
shorter fatty acid chain length in
patients with these cutaneous diseases).
The results described by Tawada et al.
(2014), in patients with atopic derma-
titis, confirms earlier reports that have
also noted a decrease in fatty acid chain
length in ceramides (Elias, 2013; van
Smeden et al., 2013). In addition, recent
studies have shown further a decrease in
long-chain free fatty acids in the stratum
corneum from patients with atopic
dermatitis (Park et al., 2012). Although
previous studies in patients with
psoriasis have reported decreases and
increases in specific subclasses of
ceramides, this is the first report of a
decrease in fatty acid chain length (van
Smeden et al., 2013). Thus, two very
common cutaneous disorders demon-
strate an inability to synthesize cera-
mides that contain long-chain fatty
acids, which contributes to the well-
recognized impairment in permeability
barrier function that is seen in patients
with both disorders.
Fatty acid synthesis normally results
in fatty acids that are 16 carbon atoms in
length. To create longer fatty acids, fatty
acid elongation is required, which is
mediated by four reactions that occur
in the endoplasmic reticulum. The first
step is rate limiting and is catalyzed by a
family of seven enzymes (elongation of
very long-chain fatty acids, ELOVLs;
Rabionet et al., 2013). The different
ELOVLs have preference based on fatty
acid chain length (Rabionet et al.,
2013). For example, ELOVL 1 prefers
fatty acids C18–24, whereas ELOVL 4
favors fatty acids with a chain length
424 carbons. The synthesis of fatty
acids longer than 24 carbons requires
ELOVL4. In mice, ELOVL 1, 3, 4, and
7 are expressed in the skin (Rabionet
et al., 2013). Both ELOVL 1 and ELOVL
4 knockout mice have impaired
permeability barrier function, and they
die shortly after birth owing to decrea-
sed ultra long–chain ceramides, result-
ing in abnormal lamellar membranes in
the stratum corneum (Rabionet et al.,
2013). Thus, the synthesis of ceramides
that contain long-chain fatty acids in the
epidermis requires ELOVLs.
In addition to ELOVLs, the synthesis
of ceramides that contain long-chain
fatty acids also requires ceramide syn-
thase 3 (CerS3; Rabionet et al., 2013).
The pathway for the biosynthesis of
ceramides is shown in Figure 1, and
CerS catalyzes the attachment of acyl-
CoAs with dihydrosphingosine. The
CerS family consists of six genes, and
these enzymes have preferences for
acyl-CoA substrates (Rabionet et al.,
2013). CerS3 has a unique preference
for C26 and C28 acyl-CoAs. CerS3
knockout mice die shortly after birth
from an impaired permeability barrier,
and, similar to ELOVL 1 and 4 knockout
mice, have decreased ultra long–
chain ceramides and abnormal lamellar
membranes (Rabionet et al., 2013).
Thus, both ELOVLs and CerS3 are
required for the synthesis of ceramides
that contain long-chain fatty acids, and
ultra long–chain ceramides are essential
for normal permeability barrier function.
The paper by Tawada et al. (2014) in
the current issue tested the effect of a
number of different cytokines on the
expression of ELOVLs and CerSs. They
report that IFN gamma reduced the
Clinical Implications
Molecular understanding of IFN gamma effects on the stratum corneum
now presents possibilities for treating patients with both psoriasis and
atopic dermatitis.
 Inhibiting the action of IFN gamma, providing ultra long–chain ceramides,
or using drugs to stimulate the expression of ELOVS and CerS3 could well
be beneficial for such patients.
 No one would have predicted 30 years ago that new molecular knowledge
about a surface membrane 10-mm thick might lead to such useful insight.
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expression of ELOVL 4 and 5 and CerS3
and 6 in cultured human kerati-
nocytes. Notably, other cytokines, inclu-
ding TNF, IL-1, IL-4, and IL-6, did not
affect the expression of these enzymes.
In addition, in human epidermal equi-
valent cultures, IFN gamma treatment
reduced the expression of ELOVL 1, 4,
6, and 7 and CerS3, 4, and 6. Signifi-
cantly, the quantity of ceramides con-
taining long-chain fatty acids was
decreased in the stratum corneum of
three-dimensional epidermal sheets
treated with IFN gamma. These results
suggest that an increase in IFN gamma,
which is well known to occur in patients
with psoriasis, atopic dermatitis, and
other cutaneous diseases, could lead to
alterations in the expression of key
enzymes, ELOVLs and CerS3, which
thereby result in abnormalities in the
synthesis of ceramides containing long-
chain fatty acids, leading to impaired
permeability barrier function that could
further exacerbate the pathologic
changes (Figure 2). It is noteworthy that
a decrease in ELOVLs has been reported
in patients with psoriasis and in an
animal model of atopic dermatitis
(Gudjonsson et al., 2010; Park et al.,
2012). It is likely that changes in the
expression of other cytokines could also
result in alterations in lipid metabolism
that adversely affect permeability barrier
function. For example, as noted above,
an increase in IL-4 in atopic dermatitis
decreases ceramide production by inhi-
biting the expression of acid sphingo-
myelinase and beta-glucocerebrosidase
(Hatano et al., 2005; Hatano et al.,
2007; Sawada et al., 2012).
It should be recognized that the
changes reported in the paper by
Tawada et al. (2014) are not the
primary abnormalities that lead to the
pathologic changes and clinical mani-
festations in patients with psoriasis or
atopic dermatitis. In the case of atopic
dermatitis, the primary abnormality in
many patients results from abnormalities
in the filaggrin gene and, in a small
number of patients, in genes regulating
serine protease activity or anti-protease
activity (Elias, 2013). In the case of
psoriasis, the primary abnormality is
still uncertain. Regardless, the primary
abnormality leads to inflammation and
abnormal permeability barrier function,
both of which increase epidermal cyto-
kine production. The increase in cyto-
kines can have beneficial effects and
adverse consequences. Tawada et al.
(2014) demonstrate that an increase in
IFN gamma can decrease the expres-
sion of key enzymes required for the
synthesis of ultra long–chain ceramides,
which are required for the formation of
a normal permeability barrier. The
decrease in ultra long–chain ceramides
can result in abnormality permeability
barrier function or worsen a defi-
cient permeability barrier. Abnormal
permeability barrier function can further
increase the epidermal production of
cytokines including IFN gamma, leading
to a positive-feedback system that can
exacerbate disease manifestations
(Figure 2). Perhaps inhibiting the action
of IFN gamma, providing ultra long–
chain ceramides, or using drugs to
stimulate the expression of ELOVS and
CerS3 could have a beneficial effect in
patients with psoriasis, atopic dermatitis,
or other cutaneous diseases where IFN
production is increased.
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Figure 1. The biosynthesis of ultra long–chain ceramides.
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Figure 2. Pathway by which IFN gamma leads to an abnormal permeability barrier.
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PHIPing Out: A Genetic Basis for
Tumor Ulceration
Jack L. Arbiser1
Ulceration is a common negative prognostic marker of solid tumors including
melanoma. The signaling basis of ulceration is being elucidated. PHIP has been
found to be amplified in wild-type melanomas, resulting in Akt activation and
aerobic glycolysis (Warburg effect), associated with ulceration. The ulceration
phenotype likely represents the genotype of the reactive oxygen driven tumor, in
which reactive oxygen drives angiopoietin-2 production, tumor growth, and
invasion. This phenotype is amenable to pharmacologic intervention.
Journal of Investigative Dermatology (2014) 134, 600–602. doi:10.1038/jid.2013.443
Ulceration is a common phenomenon
in dermatology and an adverse prognos-
tic factor in melanoma. For many years,
ulceration has been described as ‘‘a
tumor outgrowing its blood supply’’.
However, if blood supply is insufficient,
See related article on pg 783
why is ulceration an adverse prognostic
factor? We have shown that the majority
of cutaneous ulcers are not due to insuf-
ficient vascularity, but due to excess
vascularity (Arbiser et al., 2003). High
levels of matrix metalloproteinases
and unstable vasculature result in a
‘‘hostile’’ environment for epitheliali-
zation, leading to ulceration (Munavalli
et al., 2003). Ultimately, the factors
that promote ulceration are not well
understood.
Kashani-Sabet et al. have now identi-
fied pleckstrin homology domain–
interacting protein (PHIP) copy number,
initially as the top-rated gene differen-
tially expressed between metastatic
melanoma and primary melanoma
(Bezrookove et al. 2014). In this study,
they characterized PHIP as being expres-
sed at high levels in ulcerated melano-
mas. Not only was it present, the investi-
gators also demonstrated functional
consequences of PHIP overexpression.
Inhibition of PHIP led to a decrease in
aerobic glycolysis (Warburg effect). The
Warburg effect is commonly associated
with defective glucose metabolism, with
glucose being metabolized to lactate
instead of full metabolism through to
respiration. Although the ineffective
metabolism of glucose is initially counter-
intuitive in terms of tumor growth, more
recent studies have established that tumor
cells gain certain survival advantages
in exchange for switching to aerobic
glycolysis, namely NF-kB activation
and the ability to survive under extreme
hypoxia (Govindarajan et al., 2007). The
authors demonstrated the downregulation
of biomarkers of the Warburg phenome-
non, including LDH5, HIF1a, and VEGF.
Although this study demonstrates
PHIP elegantly as a potential therapeutic
target, several questions can be asked
that might provide elaboration and
answers about the role of PHIP in mela-
noma. First, is amplification the sole
mechanism of increased PHIP expres-
sion? If this is the case, adjacent genes
might provide advantages to melanoma,
because coamplification might increase
the expression of PHIP and an addi-
tional gene in a single step. Second,
what are the signaling pathways down-
stream of PHIP amplification? Glycolysis
is associated in melanoma with the
reactive oxygen–driven phenotype, in
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